Advertisement
Advertisement

ZNTL

ZNTL logo

Zentalis Pharmaceuticals, Inc. Common Stock

1.29
USD
+0.03
+2.78%
Apr 17, 15:50 UTC -4
Closed
exchange

After-Market

1.30

+0.01
+0.39%

Zentalis Pharmaceuticals, Inc. Common Stock Profile

About

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It is focused on discovering and developing small molecule therapeutics targeting cancers. The company's lead programs consist of ZN-c5, an oral selective estrogen receptor degrader for estrogen-receptor-positive, HER2-negative breast cancer which is in clinical stage. It operates principally in New York and San Diego. Zentalis Pharmaceuticals, Inc. is based in NEW YORK.

Info & Links

CEO

Julie Eastland

Headquarters

10275 SCIENCE CENTER DRIVE, SUITE 200
SAN DIEGO, CA 92121, UNITED STATES

Industry

Medical Biomedical And Genetics

Sector

Medical

Website

https://zentalis.com

Auditor

Ernst & Young LLP

Share holders

9

Employees

166

Zentalis Pharmaceuticals, Inc. Common Stock Statistics

Valuation Measures

Market Capitalization2

93.35M

Enterprise Value

59.45M

Enterprise Value/EBITDA(ttm)

-0.31

Price to Earnings Ratio(ttm)

--

Price to Sales(ttm)

--

Price to Book(mrq)

0.50

Price to Cash(ytd)

--

Profitability

Gross Margin(ttm)

50.00%

Operating Margin(ttm)

--

Profit Margin(ttm)

-37.97%

Return on Equity(ttm)

-43.91%

Return on Invested Capital(ttm)

-46.30%

Return on Assets(ttm)

-34.96%

Income Statement

Revenue(ttm)

67.42M

Revenue Per Share(ttm)

0.94

Gross Profit(ttm)

67.42M

EBITDA(ttm)3

-194.17M

Net Income Available to Common(ttm)

-165.84M

Diluted EPS(ttm)

-2.49

Share Statistics

Beta (5Y Monthly)

1.81

52-Week Change

-89.67%

S&P 500 52-Week Change

5.43%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding1

71.81M

Dividend Yield

0.00%

Float4

68.70M

% Held by Insiders

3.60%

% Held by Institutions

--

Balance Sheet

Total Cash(mrq)

371.08M

Total Cash Per Share(mrq)

5.17

Total Debt(mrq)

0.00

Total Debt/Equity(mrq)

0.00%

Current Ratio(mrq)

7.32%

Quick Ratio(mrq)

7.29%

Book Value Per Share(mrq)

4.73

Cash Flow

Operating Cash Flow Per Share(ytd)

-2.40

Free Cash Flow(ytd)

-171.02M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement